New eye drop aims to zap pink eye germs
NCT ID NCT07565103
First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This trial tests a new antibiotic eye drop called SUM-191 for bacterial conjunctivitis (pink eye). It has three parts: first, healthy volunteers get a single dose to check safety; second, healthy volunteers get multiple doses for 6 days; third, patients with pink eye get the drops for 6 days to see if it clears the infection. The study involves 426 people and is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SUM-191 eye drops
- What this could lead to
- If successful, this could lead to a new antibiotic eye drop treatment for bacterial conjunctivitis (pink eye).
- What could go wrong
- This is an early phase I/II trial, so safety and effectiveness are not yet proven. The study is small and not yet recruiting, so results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BACTERIAL CONJUNCTIVITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Austin Clinical Research Unit
RECRUITINGAustin, Texas, 78744, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.